Technology
Health
Biotechnology

Epizyme

$12.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.47 (3.77%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Epizyme and other stocks, options, ETFs, and crypto commission-free!

About

Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Read More Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Employees
124
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
1.17B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
680.62K
High Today
$13.04
Low Today
$12.42
Open Price
$12.55
Volume
167.09K
52 Week High
$18.55
52 Week Low
$5.14

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO

News

Yahoo FinanceMay 9

Hedge Funds Have Never Been This Bullish On Epizyme Inc

The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates.

234
Seeking AlphaMay 6

Epizyme beats Q1 consensus

103
Yahoo FinanceMay 6

Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 17.02% and 601.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

63

Earnings

-$0.65
-$0.53
-$0.41
-$0.29
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.